Related Experiment Video
Updated: Aug 24, 2025
Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
Published on: September 20, 2018
Expression and function of α4β7 integrin predict the success of vedolizumab treatment in inflammatory bowel disease
Ines Schneider1, Clarissa Allner1, Laura Mühl1
1Department of Medicine 1, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Abstract:
Inflammatory bowel diseases are medically intractable and require constant therapy in many cases. While a growing number of biologicals and small molecules is available for treatment, a substantial portion of patients experiences primary non-response to these compounds and head-to-head evidence for therapy selection is scarce. Thus, approaches to predict treatment success in individual patients are a huge unmet need. We had previously suggested that the expression and function of α4β7 integrin on T cells in the peripheral blood correlate to outcomes of therapy with the anti-α4β7 integrin antibody vedolizumab. Here, we conducted a translational multicenter trial to prospectively evaluate this hypothesis. In a cohort of 89 patients with inflammatory bowel disease undergoing regular therapy with vedolizumab, lower baseline expression of α4β7 was associated with short-term clinical response. Consistently, low α4β7 expression in patients achieving remission predicted sustained remission in week 30. Moreover, high dynamic adhesion of CD4+ T cells to MAdCAM-1 and high reduction of adhesion by vedolizumab in vitro at baseline were associated with clinical remission. These data substantiate the potential of α4β7 integrin function and expression to forecast outcomes of vedolizumab therapy. Further translational efforts are necessary to improve the performance of the assays and to implement the concept in clinical practice.
Insights
Predicting inflammatory bowel disease (IBD) treatment success is crucial. Lower alpha-4-beta-7 (α4β7) integrin expression on T cells predicts a positive response to vedolizumab therapy in IBD patients.
Area of Science:
- Immunology
- Gastroenterology
- Translational Medicine
Background:
- Inflammatory bowel diseases (IBD) present significant therapeutic challenges with many patients unresponsive to current treatments.
- Predictive biomarkers for selecting effective therapies, such as vedolizumab, are critically needed for personalized IBD management.
- Previous studies suggested a correlation between α4β7 integrin expression and vedolizumab treatment outcomes.
Purpose of the Study:
- To prospectively evaluate the hypothesis that α4β7 integrin expression and function predict vedolizumab treatment response in IBD patients.
- To assess the utility of α4β7 integrin as a biomarker for predicting clinical response and sustained remission.
Main Methods:
- A translational multicenter trial involving 89 IBD patients treated with vedolizumab.
- Measurement of baseline α4β7 integrin expression on peripheral blood T cells.
- Assessment of dynamic adhesion of CD4+ T cells to MAdCAM-1 and its reduction by vedolizumab in vitro.
Main Results:
- Lower baseline α4β7 integrin expression was associated with short-term clinical response to vedolizumab.
- Low α4β7 expression predicted sustained remission at week 30 in patients who initially responded.
- High baseline adhesion of CD4+ T cells to MAdCAM-1 and significant reduction of adhesion by vedolizumab correlated with clinical remission.
Conclusions:
- α4β7 integrin expression and function serve as potential predictive biomarkers for vedolizumab therapy outcomes in IBD.
- These findings support the use of α4β7 integrin as a tool for forecasting treatment success.
- Further research is needed to refine assays and integrate this predictive concept into clinical practice.
More Related Videos
07:05Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation
Published on: December 15, 2017
04:15Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of β2 Integrin Activation
Published on: February 2, 2024
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:21Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...